前列地尔联合大剂量阿托伐他汀对冠心病患者PCI术后造影剂肾病的影响-现代医学

前列地尔联合大剂量阿托伐他汀对冠心病患者PCI术后造影剂肾病的影响

单位：重庆市开州区人民医院心血管内科, 重庆 405400

分类号：R541.4

出版年·卷·期（页码）：2019·47·第八期（909-913）

摘要：

目的：探讨前列地尔联合大剂量阿托伐他汀对冠心病患者经皮冠状动脉介入（PCI）术后造影剂肾病（CIN）的影响。方法：选择重庆市开州区人民医院行PCI术的120例冠心病患者，分为空白组（n=40）、对照组（n=40）、试验组（n=40），空白组围术期使用氯化钠注射液静脉滴注，对照组联合阿托伐他汀口服，观察组联合前列地尔治疗。比较三组临床疗效。结果：试验组术后3、7 d时Cr低于对照组，术后1、3、7 d时BUN低于对照组，术后1 d时eGFR高于对照组（P<0.05）；三组CIN发生率、不良心血管事件发生率比较差异具有统计学意义（P<0.05），三组死亡率、不良反应总发生率比较无统计学意义（P>0.05）。结论：实施PCI术的冠心病患者中应用前列地尔联合大剂量阿托伐他汀效果显著。

Objective:To investigate the effectof alprostadil combined with high dose atorvastatin on contrast induced nephropathy (CIN) in patients with coronary heart disease after percutaneous coronary intervention (PCI).Methods:A total of 120 cases of coronary heart disease for PCI surgery who received therapy inChongqing Kaizhou People's Hospital were selected as research objects, they were divided into blank group (n=40), control group (n=40) and experimental group (n=40), the blank group was treated with intravenous drip of sodium chloride injection in perioperative period, the control group was combined with atorvastatin orally, the observation group was combined with alprostadil intravenous drip. The clinical efficacy was compared between the three groups.Results:Cr of the experimental group was lower than that of the control group at 3 days and 7 days after operation, BUN was lower than that of the control group at 1, 3, 7 days after operation, and eGFR was higher than that of the control group on the 1st day after operation. There was a significant difference in the incidence of CIN and adverse cardiovascular events among the three groups, but there was no significant difference in mortality and the total incidence of adverse reactions among the three groups. Conclusion:Alprostadil combined with high dose atorvastatin is effective in patients with coronary heart disease undergoing PCI.

参考文献：

[1] 王心镜,夏洪远,曹雪,等.造影剂肾病的危险因素及预防[J].现代生物医学进展,2015,15(25):4997-5000.
[2] 鲍文芳,方路,施映枫,等.造影剂肾病的研究进展[J].中国中西医结合肾病杂志,2016,17(3):277-280.
[3] 佟彦庆,裴汉军,耿立霞.造影剂肾病的研究进展[J].心血管病学进展,2016,37(6):681-684.
[4] 李婷,弓旭东,张雪峰,等.他汀预防心脏介入手术患者造影剂肾病的Meta分析[J].中国循证医学杂志,2015,15(11):1277-128.
[5] 纪芳杰,丛洪良,杨世诚,等.强化阿托伐他汀治疗对高血压合并慢性肾功能不全患者经皮冠状动脉介入治疗后对比剂肾病的预防作用[J].中华高血压杂志,2013,21(6):577-581.
[6] 葛均波,徐永健.内科学[M].北京:人民卫生出版社,2013:236-255.
[7] MYERS G L,MILLER W G,CORESH J,et al.Recommendations for improving serum creatinine measurement:A report from the laboratory working group of the national kidney disease education program[J].Clin Chem,2006,52(1):5-18.
[8] 安硕研,樊朝美,李一石.造影剂肾病的研究现状[J].中国临床药理学杂志,2015,31(13):1331-1334.
[9] 张萍,张虹,曹振华,等.急性冠脉综合征患者PCI术后造影剂肾病危险因素分析[J].山东医药,2014,54(17):64-66.
[10] 王金艳,陈红,丁文飞,等.造影剂肾病发病机制中炎症反应的探讨[J].中国病理生理杂志,2014,30(5):950-956.
[11] 段绍斌,刘娜,刘改灵,等.碘造影剂肾病的发病机制及防治进展[J].医药导报,2014,33(4):415-418.
[12] ALLEN D W,MA B,LEUNG K C,et al.Risk prediction models for contrast-induced acute kidney injury accompanying cardiac catheterization:Systematic review and meta-analysis[J].Can J Cardiol,2017,33(6):724-736.
[13] 杨勇,赵清,罗建平,等.急诊PCI术前强化阿托伐他汀治疗对造影剂肾病的预防作用[J].中国循证心血管医学杂志,2016,8(6):683-686.
[14] 钟思干,杨飞,陈爱文,等.前列地尔对合并糖尿病的冠心病患者介入治疗中造影剂肾病的预防作用研究[J].中国全科医学,2014,17(31):3720-3723.
[15] 苏陈,吴峰,张帅,等.前列地尔与还原型谷胱甘肽联合应用对冠心病患者PCI术后造影剂肾病的预防作用[J].山东医药,2015,55(31):49-51.
[16] 王萍,曾敏,郑茵,等.前列地尔联合阿托伐他汀预防老年急性冠脉综合征合并轻中度肾病患者发生造影剂肾病的效果[J].中国临床保健杂志,2017,20(4):353-356.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录